Literature DB >> 22674782

Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions.

Ryan D Kilpatrick1, Dave Gilbertson, M Alan Brookhart, Eric Polley, Kenneth J Rothman, Brian D Bradbury.   

Abstract

PURPOSE: When medications are modified in response to changing clinical conditions, confounding by indication arises that cannot be controlled using traditional adjustment. Inverse probability of treatment weights (IPTWs) can address this confounding given assumptions of no unmeasured confounders and that all patients have a positive probability of receiving all levels of treatment (positivity). We sought to explore these assumptions empirically in the context of epoetin-alfa (EPO) dosing and mortality.
METHODS: We developed a single set of IPTWs for seven EPO dose categories and evaluated achieved covariate balance, mortality hazard ratios, and confidence intervals using two levels of treatment model parameterization and weight deletion.
RESULTS: We found that IPTWs improved covariate balance for most confounders, but was not optimal for prior hemoglobin. Including more predictors in the treatment model or retaining highly weighted individuals resulted in estimates closer to the null, although precision decreased.
CONCLUSION: We chose to evaluate weights and covariate balance at a single time-point to facilitate an empirical analysis of model assumptions. These same assumptions are applicable to a time-dependent analysis, although empirical examination is not straight forward in that case. We find that the inclusion of rare treatment decisions and the high weights that result is needed for covariate balance under the positivity assumption. Removal of these influential weights can result in bias in either direction relative to the original confounding. It is therefore important to determine the reason for these rare patterns and whether inference is possible for all treatment levels.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674782     DOI: 10.1002/pds.3297

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  12 in total

1.  Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations.

Authors:  Jeffrey F Scherrer; Joanne Salas; Laurel A Copeland; Eileen M Stock; Brian K Ahmedani; Mark D Sullivan; Thomas Burroughs; F David Schneider; Kathleen K Bucholz; Patrick J Lustman
Journal:  Ann Fam Med       Date:  2016 Jan-Feb       Impact factor: 5.166

2.  The influence of prescription opioid use duration and dose on development of treatment resistant depression.

Authors:  Jeffrey F Scherrer; Joanne Salas; Mark D Sullivan; F David Schneider; Kathleen K Bucholz; Thomas Burroughs; Laurel Copeland; Brian Ahmedani; Patrick J Lustman
Journal:  Prev Med       Date:  2016-08-03       Impact factor: 4.018

3.  Estimating the average treatment effects of nutritional label use using subclassification with regression adjustment.

Authors:  Michael J Lopez; Roee Gutman
Journal:  Stat Methods Med Res       Date:  2014-11-28       Impact factor: 3.021

4.  Gender and the Association between Long-Term Prescription Opioid Use and New-Onset Depression.

Authors:  Joanne Salas; Jeffrey F Scherrer; Brian K Ahmedani; Laurel A Copeland; Kathleen K Bucholz; Mark D Sullivan; Thomas Burroughs; F David Schneider; Patrick J Lustman
Journal:  J Pain       Date:  2017-10-10       Impact factor: 5.820

5.  Characteristics of new depression diagnoses in patients with and without prior chronic opioid use.

Authors:  Jeffrey F Scherrer; Joanne Salas; F David Schneider; Kathleen K Bucholz; Mark D Sullivan; Laurel A Copeland; Brian K Ahmedani; Thomas Burroughs; Patrick J Lustman
Journal:  J Affect Disord       Date:  2016-12-21       Impact factor: 4.839

6.  Increased Risk of Depression Recurrence After Initiation of Prescription Opioids in Noncancer Pain Patients.

Authors:  Jeffrey F Scherrer; Joanne Salas; Laurel A Copeland; Eileen M Stock; F David Schneider; Mark Sullivan; Kathleen K Bucholz; Thomas Burroughs; Patrick J Lustman
Journal:  J Pain       Date:  2016-02-13       Impact factor: 5.820

7.  Prescription opioid analgesics increase the risk of depression.

Authors:  Jeffrey F Scherrer; Dragan M Svrakic; Kenneth E Freedland; Timothy Chrusciel; Sumitra Balasubramanian; Kathleen K Bucholz; Elizabeth V Lawler; Patrick J Lustman
Journal:  J Gen Intern Med       Date:  2013-10-29       Impact factor: 5.128

8.  New depression diagnosis following prescription of codeine, hydrocodone or oxycodone.

Authors:  Jeffrey F Scherrer; Joanne Salas; Kathleen K Bucholz; F David Schneider; Thomas Burroughs; Laurel A Copeland; Mark D Sullivan; Patrick J Lustman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-03-22       Impact factor: 2.890

9.  Multiple imputation procedures for estimating causal effects with multiple treatments with application to the comparison of healthcare providers.

Authors:  Gabriella C Silva; Roee Gutman
Journal:  Stat Med       Date:  2021-11-02       Impact factor: 2.373

10.  New-onset depression following stable, slow, and rapid rate of prescription opioid dose escalation.

Authors:  Joanne Salas; Jeffrey F Scherrer; Frank David Schneider; Mark D Sullivan; Kathleen K Bucholz; Thomas Burroughs; Laurel A Copeland; Brian K Ahmedani; Patrick J Lustman
Journal:  Pain       Date:  2017-02       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.